DUBLIN, Ireland & IRVINE, Calif.— Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) announced at a shareholder meetings held this week that all proposals related to Actavis’ planned acquisition of Allergan were approved by both Actavis’ and Allergan’s shareholders.

Actavis’ and Allergan’s shareholder approvals satisfy certain conditions to the closing of the transaction. The closing of the transaction is expected to occur late in the first quarter or early in the second quarter of 2015, subject to the satisfaction or waiver of certain regulatory approvals and other customary closing conditions, according to the two companies.